Literatur

• Literatur

• 1 Scragg R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultraviolet radiation. Int J Epidemiol 1981; 10: 337-341.
• 2 von Domarus Ch, Amling M. The economic importance of vitamin D supplementation of food. Osteologie 2009; 18: 112-124.
• 3 Somjen D, Weisman Y, Kohen F. et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111: 1666-1671.
• 4 Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28.
• 5 Zhou C, Lu F, Cao K. et al. Calcium-independent and 1,25(OH)₂D₃-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008; 74: 170-179.
• 6 Xiang W, Kong J, Chen S. et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-E132.
• 7 Weishaar RE, Simpson RU. Vitamin D₃ and cardiovascular function in rats. J Clin Invest 1987; 79: 1706-1712.
• 8 Chen S, Glenn DJ, Ni W. et al. Expression of the vitamin d receptor is increased in the hypertrophic heart. Hypertension 2008; 52: 1106-1112.
• 9 Bouillon R, Carmeliet G, Verlinden L. et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726-776.
• 10 Ruth JWu-Wong, Nakane M, Ma J, Cook AL. Vitamin D analogs down-regulate plasminogen activator inhibitor-1 in human coronary artery smooth muscle cells. J Thromb Haemost 2005; 03: 1545-1546.
• 11 Kawashima H. 1,25-Dihydroxyvitamin D₃ stimulates Ca-ATPase in a vascular smooth muscle cell line. Biochem Biophys Res Commun 1988; 150: 1138-1143.
• 12 Shan J, Resnick LM, Lewanczuk RZ. et al. 1,25-dihydroxyvitamin D as a cardiovascular hormone. Effects on calcium current and cytosolic free calcium in vascular smooth muscle cells. Am J Hypertens 1993; 06: 983-988.
• 13 Ishibashi K, Bukoski RD. Myosin isoform expression and force generation in cultured resistance arteries. Am J Physiol 1997; 272: C1144-C1150.
• 14 Wakasugi M, Noguchi T, Inoue M. et al. Vitamin D₃ stimulates the production of prostacyclin by vascular smooth muscle cells. Prostaglandins 1991; 42: 127-136.
• 15 Wong MS, Delansorne R, Man RY, Vanhoutte PM. Vitamin D derivatives acutely reduce endotheliumdependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2008; 295: H289-H296.
• 16 Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-581.
• 17 Suwaidi JA, Hamasaki S, Higano ST et al.. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954.
• 18 Al Mheid I, Patel R, Murrow J. et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol 2011; 58: 186-192.
• 19 Reis JP, von Muhlen D, Kritz-Silverstein D. et al. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007; 30: 1549-1555.
• 20 Pilz S, Henry RM, Snijder MB. et al. 25-hydroxyvitamin D is not associated with carotid intima-media thickness in older men and women. Calcif Tissue Int 2009; 84: 423-424.
• 21 Michos ED, Streeten EA, Ryan KA. et al. Serum 25-hydroxyvitamin d levels are not associated with subclinical vascular disease or C-reactive protein in the old order amish. Calcif Tissue Int 2009; 84: 195-202.
• 22 Yiu YF, Chan YH, Yiu KH. et al. Vitamin D deficiency is associated with depletion of circulating endothelial progenitor cells and endothelial dysfunction in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: E830-E835.
• 23 Tishkoff DX, Nibbelink KA, Holmberg KH. et al. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 2008; 149: 558-564.
• 24 Rahman A, Hershey S, Ahmed S. et al. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol 2007; 103: 416-419.
• 25 Mancuso P, Rahman A, Hershey SD. et al. 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J Cardiovasc Pharmacol 2008; 51: 559-564.
• 26 Gillor A, Groneck P, Kaiser J. et al. Congestive heart failure in rickets caused by vitamin D deficiency. Monatsschr Kinderheilkd 1989; 137: 108-110.
• 27 Pilz S, Marz W, Wellnitz B. et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008; 93 (10) 3927.
• 28 Witham MD, Crighton LJ, Gillespie ND. et al. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail 2010; 03: 195-201.
• 29 Krause R, Buhring M, Hopfenmuller W. et al. Ultraviolet B and blood pressure. Lancet 1998; 352: 709-710.
• 30 Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997; 30: 150-156.
• 31 Li YC, Kong J, Wei M. et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
• 32 Yuan W, Pan W, Kong J. et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282: 29821-29830.
• 33 Forman JP, Williams JS, Fisher ND. Plasma 25-Hydroxyvitamin D and Regulation of the Renin-Angiotensin System in Humans. Hypertension 2010; 55 (05) 1283-1288. [Epub 2010 Mar 29].
• 34 Giulietti A, van Etten E, Overbergh L. et al. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 2007; 77: 47-57.
• 35 Suzuki Y, Ichiyama T, Ohsaki A. et al. Anti-inflammatory effect of 1alpha,25-dihydroxyvitamin D(3) in human coronary arterial endothelial cells: Implication for the treatment of Kawasaki disease. J Steroid Biochem Mol Biol 2009; 113: 134-138.
• 36 Dobnig H, Pilz S, Scharnagl H. et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340-1349.
• 37 Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007; 30: 980-986.
• 38 Jorde R, Sneve M, Torjesen PA. et al. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 2010; 50 (02) 175-180. [Epub 2010 Feb 1].
• 39 Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 2005; 35: 217-224.
• 40 Aihara K, Azuma H, Akaike M. et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004; 279: 35798-35802.
• 41 Inoue M, Wakasugi M, Wakao R. et al. A synthetic analogue of vitamin D3, 22-oxa-1,25-dihydroxyvitamin D3, stimulates the production of prostacyclin by vascular tissues. Life Sci 1992; 51: 1105-1112.
• 42 Lindqvist PG, Epstein E, Olsson H. Does an active sun exposure habit lower the risk of venous thrombotic events? A D-lightful hypothesis. J Thromb Haemost 2009; 07: 605-610.
• 43 Nayha S. Cold and the risk of cardiovascular diseases. A review. Int J Circumpolar Health 2002; 61: 373-380.
• 44 Koyama T, Shibakura M, Ohsawa M. et al. Anticoagulant effects of 1alpha,25-dihydroxyvitamin D3 on human myelogenous leukemia cells and monocytes. Blood 1998; 92: 160-167.
• 45 Wu-Wong JR, Nakane M, Ma J. Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells. Thromb Res 2006; 118: 709-714.
• 46 Beer TM, Venner PM, Ryan CW. et al. High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol 2006; 135: 392-394.
• 47 Jorde R, Sneve M, Torjesen P. et al. Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D. Thromb Res 2010; 125 (05) e210-e213.
• 48 Scragg R, Khaw KT, Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr 1995; 49: 640-646.
• 49 Pfeifer M, Begerow B, Minne HW. et al. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001; 86: 1633-1637.
• 50 Scragg RK, Camargo Jr. CA, Simpson RU. Relation of serum 25-hydroxyvitamin D to heart rate and cardiac work (from the National Health and Nutrition Examination Surveys). Am J Cardiol 2010; 105: 122-128.
• 51 Puchacz E, Stumpf WE, Stachowiak EK, Stachowiak MK. Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Brain Res Mol Brain Res 1996; 36: 193-196.
• 52 Cheng S, Massaro JM, Fox CS. et al. Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes 2010; 59: 242-248.
• 53 Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370: 591-603.
• 54 Pilz S, Tomaschitz A, Ritz E, Pieber TR. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 2009; 06: 621-630.
• 55 Margolis KL, Ray RM, Van Horn L. et al. Effect of calcium and vitamin D supplementation on blood pressure: the Women’s Health Initiative Randomized Trial. Hypertension 2008; 52: 847-855.
• 56 Bourlon PM, Billaudel B, Faure-Dussert A. Influence of vitamin D3 deficiency and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol 1999; 160: 87-95.
• 57 Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 2000; 47: 383-391.
• 58 Nyomba BL, Bouillon R, De Moor P. Influence of vitamin D status on insulin secretion and glucose tolerance in the rabbit. Endocrinology 1984; 115: 191-197.
• 59 Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986; 119: 84-90.
• 60 Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79: 820-825.
• 61 Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27: 2813-2818.